Manipal Health Enterprises has achieved a significant market milestone, with its market capitalization crossing ₹1 trillion after a sharp rally in stock price. According to latest reports from Business Standard, the healthcare company's market cap stood at ₹1.05 trillion at 12:00 noon on Friday, representing a substantial increase from its previous achievement. The stock was trading 0.43% higher at ₹800.90, outperforming the BSE Sensex which rose only 0.10%. This represents a 13% rally in the past week and a 38% premium over its issue price of ₹590 per share since its stock market debut on August 5, 2026.
Manipal Health Enterprises delivered robust financial performance in Q1FY27, with revenue from operations growing 38.1% year-on-year to ₹3,091 crore. The company's EBITDA increased 26.4% YoY to ₹749 crore, demonstrating strong operational momentum that contributed to its market cap achievement. According to Business Standard, the performance was supported by sustained patient demand, growth in high-acuity specialties, and improved occupancy across the expanded network. Inpatient and outpatient volumes grew 38.8% and 26.0% respectively during the quarter, while occupancy improved by 290 basis points YoY to 65.0% as the network continued to absorb recently added capacity.
HSBC Global Investment Research initiated coverage on Manipal Hospitals with a 'Buy' rating and a target price of ₹1,000 per share, implying a 26% upside from current market levels. As reported by The Hindu BusinessLine, the brokerage cited multiple growth levers ahead including improving hospital utilisation, Sahyadri turnaround, higher-margin speciality mix and deleveraging. HSBC expects adjusted PAT to grow nearly threefold to ₹2,250 crore over FY26-29E, with net debt-to-EBITDA improving to 0.7x in FY27E from 3.7x in FY26. The brokerage's bull-case scenario implies a valuation of ₹1,250 per share, while their bear-case scenario suggests a valuation of ₹555 per share. The company is currently trading at 27.5x our FY28 EBITDA estimate, with improvement in EBITDA margins for Sahyadri Hospitals identified as a key re-rating catalyst.
According to The Hindu BusinessLine, Manipal Health is positioned for sustained growth through strategic expansion and operational improvements. The company has doubled bed capacity since FY23 with around 5,400 beds added mainly through M&A, representing a 19.3% CAGR in bed capacity. After the addition of around 5,400 beds, mainly via M&A during FY23-26, the company expects to focus on improving asset utilisation and operational profitability. HSBC expects the company to add around 2,500 beds during FY27-30, including 24% brownfield beds, to boost presence in target markets. The company maintains its leadership in complex medical procedures, with CONGO-R revenue growing at 37.3% CAGR over FY24-26, accounting for 64% of network revenue in FY26. HSBC estimates revenue and EBITDA to grow at CAGRs of 17.9% and 19.3% respectively over FY26-29E.
Manipal Health is well-positioned for financial improvement through strategic debt management and operational efficiency. The company plans to repay ₹5,550 crore of debt using proceeds from the IPO in Q2FY27, as reported by The Hindu BusinessLine. HSBC expects the net debt-to-EBITDA ratio to improve sharply to 0.7x in FY27E from 3.7x in FY26, before the IPO. With lower capex intensity, the brokerage expects Return on Capital Employed (RoCE) to reach 13.1% by FY29E, up from 12.6% in FY26. The company operates as India's largest private hospital network with an installed bed capacity of 13,140 as of Q1FY27, backed by Singapore's Temasek Holdings. The company serves approximately 8 million patients annually across its pan-India network of 50 hospitals with over 13,400 licensed beds.
